evaluations of sensory attribute of intranasal corticosteroid sprays in healthy volunteers.

CONCLUSION: The sensory effects of INCSs were not as unfavorable as we thought. PMID: 29553112 [PubMed - in process]
Source: Allergology International - Category: Allergy & Immunology Tags: Arerugi Source Type: research

Related Links:

Publication date: Available online 17 February 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): James H. Clark, Fuad M. Baroody, Robert M. NaclerioAbstractSinonasal disease in its multiple forms affects billions of people worldwide. Although physicians train to precisely diagnose a patient and then treat appropriately, the sheer number of people afflicted with sinonasal disease precludes this approach. We argue that patients should first be treated with an intranasal corticosteroid for 2 weeks. Based on their perceived response, they should be triaged. Those who respond well can be instruct...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
ConclusionsSpecialist-diagnosed CC was associated with considerable disease burden, particularly among those with both respiratory disease and GERD. Additionally, CC burden was more pronounced than in matched non-cough patients.
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: February 2020Source: The Journal of Allergy and Clinical Immunology: In Practice, Volume 8, Issue 2Author(s): Anne M. Fitzpatrick, Bradley E. Chipps, Fernando Holguin, Prescott G. WoodruffAlthough the term “asthma” has been applied to all patients with airway lability and variable chest symptoms for centuries, phenotypes of asthma with distinct clinical and molecular features that may warrant different treatment approaches are well recognized. Patients with type 2 (T2)-“high” asthma are characterized by upregulation of T2 immune pathways (ie, IL-4 and IL-13 gene sets) and eosinophi...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Options to achieve oral corticosteroid (OCS)-sparing have been triggering increasing interest since the 1970s because of the side-effects of OCSs, and this has now become achievable with biologics. The Société de Pneumologie de Langue Francaise workshop on OCSs aimed to conduct a comprehensive review of the basics for OCS use in asthma and issue key research questions. Pharmacology and definition of regular use were reviewed by the first working group (WG1). WG2 examined whether regular OCS use is associated with T2 endotype. WG3 reported on the specificities of the paediatric area. Key "research stateme...
Source: European Respiratory Review - Category: Respiratory Medicine Authors: Tags: Asthma and allergy Review Source Type: research
Abstract Pneumocystis jiroveci remains an important fungal pathogen in a broad range of immunocompromised hosts. The natural reservoir of infection remains unknown. Pneumocystis jiroveci Pneumonia (PJP) develops via airborne transmission or reactivation of inadequately treated infection. Nosocomial clusters of infection have been described among immunocompromised hosts. Subclinical infection or colonization may occur. Pneumocystis pneumonia occurs most often within 6 months of organ transplantation and with intensified or prolonged immunosuppression, notably with corticosteroids. Infection is also common during ne...
Source: Respiratory Care - Category: Respiratory Medicine Authors: Tags: Semin Respir Crit Care Med Source Type: research
Publication date: Available online 30 January 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Jian Guo Hong, Gustavo Wandalsen, Kevin R. Murphy, Désirée Larenas-Linnemann, Ahmed El Beleidy, Olga Vitalievna Zaytseva, Søren E. PedersenAbstractAlthough nebulized corticosteroids (NebCS) are a key treatment option for young children with asthma or viral-induced wheezing (VIW), there are no uniform recommendations on their best use. This systematic review aims to clarify the role of NebCS in children aged ≤5 years for the management of acute asthma exacerbations, asthma m...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Publication date: Available online 15 January 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Yong Suk Jo, Yong Il Hwang, Kwang Ha Yoo, Tae-Hyung Kim, Myung Goo Lee, Sang Haak Lee, Kyeong-Cheol Shin, Kwang Ho In, Hyoung Kyu Yoon, Chin Kook Rhee, Korean Asthma Research Group &KOCOSS cohortBackgroundFew reports have investigated the efficacy of using inhaled corticosteroid (ICS)-containing inhalers to treat patients with asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO).ObjectiveTo investigate the effect of ICS treatment on patients with ACO using 5 sets of diagnostic cri...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Semin Respir Crit Care Med 2020; 41: 141-157 DOI: 10.1055/s-0039-3399559 Pneumocystis jiroveci remains an important fungal pathogen in a broad range of immunocompromised hosts. The natural reservoir of infection remains unknown. Pneumocystis jiroveci Pneumonia (PJP) develops via airborne transmission or reactivation of inadequately treated infection. Nosocomial clusters of infection have been described among immunocompromised hosts. Subclinical infection or colonization may occur. Pneumocystis pneumonia occurs most often within 6 months of organ transplantation and with intensified or prolonged immunosuppression, notabl...
Source: Seminars in Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Tags: Review Article Source Type: research
Publication date: Available online 28 January 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Gayatri B. Patel, Robert C. Kern, Jonathan A. Bernstein, Park Hae-Sim, Anju T. PetersAdvances in understanding the pathogenic mechanisms of both rhinitis and chronic rhinosinusitis have resulted in new treatment options, especially for chronic rhinosinusitis. A review of relevant medical and surgical clinical studies shows that intranasal corticosteroids, antihistamines, and allergen immunotherapy continue to be the best treatments for chronic rhinitis. Dupilumab is the first biologic approved for...
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Are asthma patients who use inhaled corticosteroids at an increased risk for pneumonia and hospitalization?BMC Pulmonary Medicine
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Pulmonary Medicine Journal Article Source Type: news
More News: Allergy | Allergy & Immunology | Corticosteroid Therapy | Flonase | Mometasone | Nasonex | Study